Effect of Nicotine on the Pharmacokinetics of Levodopa

Clinical Neuropharmacology

Volumn 36, Issue 2, 2013, Pages 46-51

  Kyaw, Win Thiri ^a   Nagai, Masahiro ^a   Kaneta, Mika ^a   Kubo, Madoka ^a   Nishikawa, Noriko ^a   Tsujii, Tomoaki ^a   Iwaki, Hirotaka ^a   Nomoto, Masahiro ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

levodopa carbidopa; nicotine; Parkinson disease; transporter

Indexed keywords

ACETIC ACID; BENSERAZIDE PLUS LEVODOPA; CARBON 13; COTININE; LEVODOPA; NICOTINE PATCH;

ADULT; ARTICLE; BREATH ANALYSIS; CELL STRAIN CACO 2; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG TRANSPORT; DRUG UPTAKE; ENTERIC FEEDING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE CELL; MALE; MONOLAYER CULTURE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; CACO-2 CELLS; CROSS-OVER STUDIES; DRUG INTERACTIONS; DYSKINESIAS; GASTRIC EMPTYING; HUMANS; INTESTINAL MUCOSA; LEVODOPA; MALE; MIDDLE AGED; NICOTINE; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875468108     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31827fd9cd     Document Type: Article

References (28)

1. Quik M, O'Leary K, Tanner CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord 2008;23:1641-1652.
2. Mitsuoka T, Kaseda Y, Yamashita H, et al. Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism. Hiroshima J Med Sci 2002;51:33-39.
3. Huang LZ, Grady SR, Quik M. Nicotine reduces L-DOPAYinduced dyskinesias by acting at beta2&z.ast; nicotinic receptors. J Pharmacol Exp Ther 2011;338:932-941.
4. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001;16:1041-1047.
5. Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause WrandomW fluctuations of parkinsonian mobility. Neurology 1988;38:419-421.
6. Waller DG, Usman F, Renwick AG, et al. Oral amino acids and gastric emptying: an investigation of the mechanism of levodopa-induced gastric stasis. Br J Clin Pharmacol 1991;32:771-773.
7. Robertson DR, Renwick AG, Wood ND, et al. The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 1990;29:47-53.
8. Oxender DL, Christensen HN. Evidence for two types of mediation of neutral and amino-acid transport in Ehrlich cells. Nature 1963;197:765-767.
9. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990;70:43-77.
10. Gomes P, Soares-da-Silva P. L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. Brain Res 1999;829(1-2):143-150.
11. Fraga S, Sampaio-Maia B, Serrão MP, et al. Regulation of apical transporter of L-DOPA in human intestinal Caco-2 cells. Acta Physiol Scand 2002;175:103-111.
12. Nishikawa N, Nagai M, Tsujii T, et al. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol 2012;35:182-184.
13. Schneider JS, Van Velson M, Menzaghi F, et al. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 1998;43:311-317.
14. Schneider JS, Pope-Coleman A, Van Velson MA, et al. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord 1998;13:637-642.
15. Ling H, Petrovic I, Day BL, et al. Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson's disease. J Neurol 2012;259:2419-2423.
16. Kelton MC, Kahn HJ, Conrath CL, et al. The effects of nicotine on Parkinson's disease. Brain Cogn 2000;43:274-282.
17. Villafane G, Cesaro P, Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 2007;14:113-1316.
18. Vieregge A, Sieberer M, Jacobs H, et al. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001;57:1032-1035.
19. Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46:1051-1054.
20. Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29:61-67.
21. Wong PW, Kadakia SC, McBiles M. Acute effect of nicotine patch on gastric emptying of liquid and solid contents in healthy subjects. Dig Dis Sci 1999;44:2165-2171.
22. Gritz ER, Ippoliti A, Jarvik ME, et al. The effect of nicotine on the delay of gastric emptying. Aliment Pharmacol Ther 1988;2:173-178.
23. Bordia T, Campos C, Huang L, et al. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2008;327:239-247.
24. Bordia T, Campos C, Mclntosh M, et al. Nicotine receptor-mediated reduction in L-DOPA induced dyskinesias may occur via desensitization. Pharmacol Exp Ther 2010;333:929-938.
25. Quik M, Cox H, Parameswaran N, et al. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62:588-596.
26. Müller T. The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson's disease. Clinical Medicine Insights: Therapeutics 2010;2:155-168.
27. Alexander GM, Schwartzman RJ, Grothusen JR, et al. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys. Neurology 1994;44:1491-1499.
28. Frankel J, Kempster PA, Bovingdon M, et al. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 1989;52:1063-1067.